Malaria Vaccine Candidates and Their Antibody Response
Author Information
Author(s): Miura Kazutoyo, Keister David B, Muratova Olga V, Sattabongkot Jetsumon, Long Carole A, Saul Allan
Primary Institution: National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
Hypothesis
The transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
Conclusion
ELISA data may be used as a surrogate for the MFA to evaluate transmission-blocking vaccine efficacy.
Supporting Evidence
- Anti-Pfs25 and anti-Pvs25 sera showed that ELISA antibody units correlate with the percent reduction in the oocyst density per mosquito.
- Antibody levels correlated with the number of mosquitoes that failed to become infected.
- The study established a method to evaluate MSTB vaccine potential for large numbers of samples.
Takeaway
This study shows that the more antibodies you have from a malaria vaccine, the better it can stop the disease from spreading.
Methodology
Rabbit and monkey sera were tested for antibody levels using ELISA and their biological activity was evaluated using a mosquito membrane-feeding assay.
Potential Biases
Potential biases may arise from the small number of animal models used and the specific conditions under which the assays were conducted.
Limitations
The study's findings may not be generalizable to all populations due to the limited sample size and specific conditions of the assays.
Participant Demographics
Four rabbits and ten rhesus monkeys were used in the study.
Statistical Information
P-Value
0.057
Confidence Interval
95% CI: 677 to 1562
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website